SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 7, 2003; DOI 10.1182/blood-2003-05-1611. This Article Full Text (PDF) All Versions of this Article: 2003-05-1611v1 103/1/58    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by le Maignan, C. Articles by Andrieu, J.-M. Search for Related Content PubMed PubMed Citation Articles by le Maignan, C. Articles by Andrieu, J.-M. Social Bookmarking                   What's this? Submitted May 20, 2003 Accepted July 28, 2003 Three cycles of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) or Epirubicin, Bleomycin, Velban, and Methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin's disease: 10-year results of a randomized trial Christine le Maignan, Bernard Desablens, Vincent Delwail, Mahmoud Dib, Christian Berthou, Magda Vigier, Christiane Ghandour, Said Atmani, Philippe Casassus, Herve Maisonneuve, Annick Le Mevel, Catherine Traulle, Marc Bernard, Josette Briere, Pierre Colonna, and Jean-Marie Andrieu* Departement de Cancerologie Medicale, Hopital Europeen Georges Pompidou, Paris, France Departement d'Hematologie, Hopital Sud, Amiens, France Departement d'Hematologie, Hopital Jean Bernard, Poitiers, France Departement d'Hematologie, Centre Hospitalier-Universitaire, Angers, France Departement d'Hematologie, Hopital Morvan, Brest, France Departement d'Hematologie, Hotel Dieu, Nantes, France Centre anti-cancereux, Rennes, France Departement d'Hematologie, Hopital Beaujon, Clichy, France Departement d'Hematologie, Hopital Avicenne, Bobigny, France Departement de Medecine A, Centre hospitalier Departemental, La Roche sur Yon, France Centre Rene Gauducheau, Nantes, France Centre Leon Berard, Lyon, France Departement d'Hematologie, Hopital Pontchaillou, Rennes, France Departement d'Anatomo-pathologie, Hopital Saint Louis, Paris, France * Corresponding author; email: cancero.egp{at}egp.ap-hop-paris.fr. From 1990 to 1996, 386 adult patients with early/intermediate Hodgkin's disease (HD) were randomly assigned to receive three cycles of Adriamycin, Bleomycin, Vinblastin, Dacarbazine (an alkylating agent), and Methylprednisolone (ABVDm, arm A) or Epirubicin, Bleomycin, Vinblastin, Methotrexate, and Methylprednisolone (EBVMm, arm E), a combination without alkylating agent. Responding patients received extended field radiation therapy (RT). Post-chemotherapy complete remission and 10-year freedom from progression rates were higher in arm A (79.5% and 91.4%) than in arm E (70.4%, p=0.04 and 80%, p<.002).HD mortality (HDM), treatment-related mortality (TRM) and overall survival (OS) were similar in both arms (A 2.1%, 7.5% and 90.4%; B 3.9%, 5.5% and 90.3%). However TRM and OS rates were lower in patients aged 40 years (p<0.005) reflecting the increasing incidence of background fatal events with increasing age. Finally event-free survival (EFS) was higher in arm A (84.6%) than in arm E (74.9%, p<0.02). In patients aged <40 years of arm A (74%), 10-year EFS and OS rates were 88.9% and 95.4% with HDM and TRM rates as low as 0.7% and 3%. Three courses of ABVDm plus RT are the best available option for treating early or intermediate HD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF] P. Feugier, E. Labouyrie, M. Djeridane, A. Jenabian, V. Dubruille, C. Berthou, C. Ghandour, B. Desablens, Y. Chait, P. Casassus, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation Blood, November 1, 2004; 104(9): 2675 - 2681. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020